Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT00967200
First received: August 26, 2009
Last updated: November 23, 2015
Last verified: November 2015

August 26, 2009
November 23, 2015
November 2003
July 2009   (final data collection date for primary outcome measure)
Pathophysiology of gliomas [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic
Pathophysiology of gliomas and identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00967200 on ClinicalTrials.gov Archive Site
Identification of molecular [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic
Not Provided
Not Provided
Not Provided
 
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

OBJECTIVES:

Primary

  • To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.

Secondary

  • To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.

OUTLINE: This is a multicenter study.

Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Pathophysiology of gliomas and identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic
Central Nervous System Lymphoma
  • Other: laboratory biomarker analysis
    laboratory biomarker analysis
  • Other: pharmacogenomic studies
    pharmacogenomic studies
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
180
November 2015
July 2009   (final data collection date for primary outcome measure)

Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing

Exclusion :

No concurrent participation in other trials that require a period of exclusion

Both
18 Years to 120 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00967200
7745
No
Not Provided
Not Provided
University Hospital, Montpellier
University Hospital, Montpellier
Not Provided
Principal Investigator: Luc Bauchet, MD University Hospital, Montpellier
University Hospital, Montpellier
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP